SEHK:1672Biotechs
Assessing Ascletis Pharma (SEHK:1672) Valuation After Positive Acne Data And Denifanstat NDA Acceptance
Ascletis Pharma (SEHK:1672) is back in focus after reporting favorable long term safety data from its Phase III acne drug denifanstat and confirming that China’s regulator has accepted its New Drug Application.
See our latest analysis for Ascletis Pharma.
The acne data and NDA progress come on the back of an active few weeks across its GLP 1 and metabolic pipeline. The share price has moved accordingly, with a 30 day share price return of 19.79% and 90 day share price return of 40.67%, adding...